In human specimens, the downregulation of HMGA1, E2F1, and vimentin, analyzed by IHC, compared with the basal levels found in the biopsies revealed that trabectedin therapy reduces the mesenchymal markers of the tumor. The gene discussed is E2F1; the disease is neoplasm.